3-Ethyl-4-Methyl-N-[2-(4-{[(4-Methylcyclohexyl)Carbamoyl]Sulfamoyl}Phenyl)Ethyl]-2-Oxo-2,5-Dihydro-1H-Pyrrole-1-Carboxamide

In low-dose direct compression processing, glimepiride constitutes less than 1.0% w/w of the total tablet mass at the 1 mg strength, creating a content uniformity risk measured by acceptance value (AV) per USP <905>. The API is pre-micronized to a particle size distribution with D90 ≤ 20 µm and a specific surface area exceeding 4 m²/g as determined by nitrogen adsorption (ISO 9277:2022). A two-stage blending sequence within a 600 L V-shell tumble blender operating at 12 rpm for 180 seconds is implemented: pre-mixing glimepiride with an equal mass of directly compressible lactose monohydrate (FlowLac® 100) sieved through an 800 µm screen, followed by addition of microcrystalline cellulose (Avicel® PH-102), croscarmellose sodium (2.0% w/w), and colloidal silicon dioxide (0.5% w/w). Tablet compression on a rotary press equipped with 6 mm round concave tooling applies a main compression force within 5–15 kN to achieve tablet hardness of 40–70 N. Friability is maintained below 0.5% after 100 drops (USP <1216>). To mitigate dissolution slowdown, magnesium stearate (vegetable grade, 0.5–1.0% w/w) is introduced in the final 60 seconds of blending; extended lubricant mixing beyond 5 minutes causes a measurable drop in percent dissolved at 30 minutes in pH 6.8 phosphate buffer (USP Apparatus II, 50 rpm) due to hydrophobic film coating. Quantitative data illustrating this sensitivity are provided in Table 1.

Environmental controls during processing set a limit of RH ≤ 55% and temperature 22 °C ± 3 °C, because glimepiride shows limited hygroscopicity but fine particles agglomerate above this threshold, increasing blend segregation tendency in the hopper. Additional in-process blending uniformity testing using stratified sampling of 10 points yields a relative standard deviation (RSD) < 5.0%. Degradation product monitoring per ICH Q3B(R2) confirms total impurities below 0.5% after direct compression, with an HPLC method using a C18 column, 5 µm, 250 × 4.6 mm, mobile phase acetonitrile–phosphate buffer pH 2.5 (45:55), UV detection at 228 nm. The terminal product is a round, white to off-white uncoated tablet meeting USP monograph for glimepiride tablets, with immediate-release intended for blood glucose regulation in type 2 diabetes mellitus.

Wet Granulation Endpoints and Dissolution Specification Compliance

Wet granulation of glimepiride in a high-shear mixer-granulator represents the preferred route when direct compression encounters segregation or low-dose uniformity failures. The API is premixed with lactose monohydrate and corn starch (85:15 ratio) for 2 minutes at an impeller speed of 150 rpm in a 25 L bowl of a Diosna P1-6 type granulator. A binder solution of hypromellose (HPMC 2910, 3 mPa·s) in purified water at 8% concentration is sprayed at 80 g/min while the impeller is raised to 350 rpm and the chopper activated at 1800 rpm. Monitoring the integrated power consumption curve of the main motor reveals a plateau corresponding to an endpoint value of 6.5–8.0 kW for a batch size of 10 kg; granulation beyond this point drives excessive densification, producing hard granules that survive wet sieving through a 2.0 mm screen and result in tablets with dissolution failure at 30 min (Q < 70%). Drying in a fluid-bed dryer at an inlet temperature of 55 °C until loss on drying reaches 1.5–2.5% w/w (USP <731>) is followed by dry sieving through a 0.8 mm oscillating granulator. Final blend lubrication with sodium stearyl fumarate (1.5% w/w) rather than magnesium stearate is preferred to avoid dissolution delays; sodium stearyl fumarate does not form a hydrophobic film under extended mixing up to 20 min. Tablets compressed at 10–18 kN carry specifications identical to the direct compression approach yet show an AV consistently below 8.0 in content uniformity testing. A non-functional film coat of Opadry® II white (3.0% weight gain) is applied in a perforated pan coater. The dissolution test (USP Apparatus II, paddle, 50 rpm, 900 mL pH 6.8 buffer) requires Q=80% at 30 min; batch data demonstrates > 90% release by 15 min when API particle size is maintained below D50 10 µm. Incompatibility alert: combining glimepiride with pregelatinized starch above 10% w/w in the granulation phase generates a moisture-retentive matrix that slows dissolution upon storage under 40°C/75% RH conditions, disqualifying the product from ICH stability conformance.

What Drives the Interface Integrity in Glimepiride-Metformin Bilayer Tablets?

In bilayer tableting of glimepiride-metformin fixed-dose combinations, mechanical integrity of the interface becomes critical. The metformin layer, occupying roughly 85% of the tablet mass, is processed via high-shear wet granulation using a hydroalcoholic solution of povidone K30 as binder, dried to LOD 2.0–3.5%, and lubricated with stearic acid (1.0% w/w) to avoid negative interaction with the acidic salt. The glimepiride layer, prepared identically to the direct compression or wet granulation route described earlier, is compacted to a thickness of 1.2–1.5 mm in the first fill station under a pre-compression force of 2–4 kN. The second fill shoe deposits the metformin granulation, and the combined mass is compressed at a main force of 18–25 kN using 16 × 8 mm oval tooling on a Kikusui Libra2 bilayer rotary press equipped with automatic weight control. Interface fracture energy, assessed via diametral compression test, must exceed 0.5 J/m² to avoid core splitting during aqueous film coating. Visual inspection of cross-sections under 10× magnification after friability testing (USP <1216>) exposes no delamination. Environmental control is tight because metformin hydrochloride is hygroscopic; processing rooms are maintained at 25 °C and RH ≤ 40%. A key incompatibility arises from the acidic nature of metformin HCl (a 1% w/w aqueous solution has pH ~ 3) catalyzing sulfonamide-urea cleavage in glimepiride; hence direct contact between the two drugs is avoided through a middle barrier layer of anhydrous lactose (5.0 mg) placed automatically by the layer press. Dissolution testing for each layer follows separate compendial chapters: glimepiride is tested in phosphate buffer pH 6.8 with a 200 mL vessel modification (USP Apparatus I, 100 rpm) due to low dose, while metformin complies with 0.1 N HCl conditions; both reach Q=80% within 30 minutes. Stability protocols conform to ICH Q1A(R2); degradation products of glimepiride are controlled as per the USP monograph, with specified limit for impurity B (N-[4-[2-(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl]phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea) not exceeding 0.5%. Production-scale observations on bilayer presses indicate that static electricity build-up on the glimepiride layer can cause sticking to the upper punch; incorporation of 0.1% sodium lauryl sulfate in the layer formulation eliminates this electrostatic adhesion artifact.

When formulating immediate-release glimepiride tablets for BCS II drug dissolution enhancement, particle size reduction becomes non-negotiable. A fluid-energy mill (Jet-O-Mizer, Model 0400, Sturtevant Inc.) operated with compressed nitrogen at a feed rate of 0.5–2.0 kg/h and venturi pressure of 7 bar yields micronized API with a volume-median diameter (Dv50) < 3 µm and span (Dv90-Dv10)/Dv50 ≤ 2.1. Particle size distribution is verified by laser diffractometry according to ISO 13320:2020 using a Malvern Mastersizer 3000 equipped with a dry dispersion unit at 2.0 bar air pressure. The specific surface area increases from 0.8 m²/g (unmilled) to approximately 6.8 m²/g (5-point BET, ISO 9277:2022). Powder X‑ray diffraction (XRD) confirms retention of crystalline form I, with amorphous content quantified below 2.0% by dynamic vapour sorption (DVS-1, Surface Measurement Systems) to prevent recrystallization-driven agglomeration. A manufacturing risk emerges from electrostatic charging of micronized particles; blending with 0.2% w/w colloidal silicon dioxide (Aerosil® 200) prior to processing dissipates charge and restores flow. Table 2 summarizes a gradient study of milling parameters and resultant dissolution behavior.

The micronized API is immediately double-bagged in LDPE liners inside a sealed HDPE drum with silica gel desiccant, stored at ≤ 25 °C and RH ≤ 30%. Any delay beyond 4 hours before formulation leads to substantial particle agglomeration confirmed by SEM. In tablet formulation, the micronized drug substance is incorporated in a pre-blend with lactose monohydrate before final mixing; dissolution acceptance criteria in pH 6.8 phosphate buffer (USP Apparatus II, 50 rpm) require Q = 85% at 15 min, a threshold achievable only when the Dv90 stays below 10 µm and the surfactant sodium lauryl sulfate is present at 0.05% w/w in the dissolution medium. Compliance with FDA Guidance for Industry BCS-based biowaivers is partially supported, though glimepiride’s BCS classification as a Class II low-solubility high-permeability drug mandates a dissolution similarity (f2) comparison against the reference product across three pH media (1.2, 4.5, 6.8) for any biowaiver request. In practice, pilot batches manufactured with micronized API meeting Dv50 2.0–4.0 µm demonstrate f2 values > 55 in all media, confirming the size-reduction strategy aligned with EMA guideline on bioequivalence.

Establishing Chromatographic Purity and Assigning Assay Values for a Glimepiride Working Standard

For analytical development and quality control release testing, a well-characterized batch of glimepiride meeting USP Glimepiride RS specifications serves as a working standard. Purity assignment by a mass-balance approach involves HPLC area percent (excluding solvent and inorganic impurities), loss on drying (USP <731>, 105°C for 3 hours, LOD < 0.5%), water content by Karl Fischer titration (≤ 0.2%), and residual solvents by headspace GC (ICH Q3C, Class 3 solvents ≤ 0.5%). System suitability testing under the official monograph method on a 4.6 × 250 mm, 5 µm L1 column with UV detection at 228 nm requires resolution between glimepiride and its specified impurity B of not less than 2.0, and the column efficiency for the main peak must exceed 15,000 theoretical plates. The standard is stored in a desiccator over phosphorus pentoxide protected from light; weightings are corrected for purity and volatile matter. This precisely valorized material enables accurate quantification of glimepiride in finished tablets and stability samples, securing compliance with 21 CFR Part 211 and pharmacopoeial harmonization.

If a Biowaiver is Not Feasible: Manufacturing Pilot Batches for In Vivo BE Studies

When a biowaiver is not applicable due to product design differences or regulatory caution, a clinical-scale pilot batch of glimepiride tablets, most commonly 2 mg strength, is manufactured under full GMP conditions to support a comparative in vivo bioavailability study. The process duplicates the finalized commercial route—either direct compression or wet granulation—with an exhaustive documentary trail capturing all equipment IDs (e.g., Glatt fluid-bed dryer, Fette P1010 press), in-process readings and environmental logs. The batch size is set at not less than 100,000 tablets or one-tenth of the intended production scale, as recommended in EMA/CHMP/QWP/545525/2017. API particle size is locked to the same micronized specification (Dv50 2.0–3.5 µm) used in earlier formulation studies; a pre-shipment retain sample is retained for dissolution profiling. Multi-point dissolution profiles are generated in pH 1.2 (0.1 N HCl), pH 4.5 acetate buffer, and pH 6.8 phosphate buffer using USP Apparatus II (paddle) at 75 rpm, with samples pulled at 10, 15, 20, 30, 45 min and analyzed by a validated HPLC method. The similarity factor f2 is calculated according to FDA guidance on dissolution testing; a value of > 50 in all three media, together with consistent disintegration times (< 5 minutes in water at 37 °C), supports the acceptability of the test product as equivalent to the reference. The entire batch is packaged in blister packs (PVC/PVDC/Alu) to match the intended market presentation, and placed on accelerated stability at 40 °C/75% RH per ICH Q1A(R2) while bio-study initiation is conditioned on favorable assay, dissolution, and impurity data collected at baseline. One critical failure mode encountered at pilot scale is punch filming on the lower punch tip due to inadequate lubrication when using a reduced lubricant level intended to maximize dissolution; the remedy involves raising sodium stearyl fumarate to 1.5% and adjusting tooling surface specification to a 0.025 µm Ra polished chrome finish. All operations are fully auditable and records are compiled in a CTD Module 3 format.